( NASDAQ-NMS:PCYC )

News from pharmacyclics, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 28, 2015, 09:00 ET Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

 Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib...


May 22, 2015, 08:04 ET European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...


May 13, 2015, 17:21 ET New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that ibrutinib (IMBRUVICA®) single-agent and combination data will be featured in...


May 01, 2015, 09:15 ET Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates

Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter ended March 31, 2015, as well as general...


Apr 20, 2015, 09:00 ET Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models

 Ibrutinib (IMBRUVICA®) data presented yesterday by Pharmacyclics, Inc. (NASDAQ: PCYC) at the American Association for Cancer Research...


Apr 20, 2015, 08:45 ET IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that IMBRUVICA® (ibrutinib) follow-up data in treatment-naive (TN) and relapsed/refractory...


Apr 09, 2015, 09:00 ET New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's...


Apr 01, 2015, 09:00 ET Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib...


Mar 19, 2015, 09:00 ET New ibrutinib (IMBRUVICA®) Data to be Presented at American Association for Cancer Research (AACR) Meeting

  Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA®) will be...


Feb 27, 2015, 14:45 ET Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK)...


Feb 27, 2015, 14:30 ET In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

Pharmacyclics, Inc. (NASDAQ: PCYC) today highlighted findings from a pre-clinical study published in the Proceedings of the National Academy of...


Feb 18, 2015, 16:01 ET Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates

 Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter and year ended December 31, 2014, as well...


Feb 17, 2015, 09:00 ET IMBRUVICA® (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with IMBRUVICA® (ibrutinib) was associated with an 88% overall response...


Feb 12, 2015, 10:40 ET Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results

  Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for...


Jan 29, 2015, 11:43 ET U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA®...


Jan 12, 2015, 17:45 ET Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook

 Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product...


Jan 05, 2015, 09:00 ET IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with single-agent IMBRUVICA®...


Dec 22, 2014, 09:00 ET Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee...


Dec 12, 2014, 09:00 ET Pharmacyclics Named 2014 Outstanding Company by BayBio

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company...


Dec 09, 2014, 09:00 ET IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a...


Dec 09, 2014, 09:00 ET Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...


Dec 09, 2014, 09:00 ET IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...


Dec 08, 2014, 21:30 ET IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...


Dec 08, 2014, 21:02 ET Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...